Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Change in Cash (2016 - 2025)

Historic Change in Cash for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to $4.8 million.

  • Anika Therapeutics' Change in Cash rose 116233.48% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.4 million, marking a year-over-year increase of 4714.48%. This contributed to the annual value of -$15.7 million for FY2024, which is 1670.13% down from last year.
  • According to the latest figures from Q3 2025, Anika Therapeutics' Change in Cash is $4.8 million, which was up 116233.48% from -$204000.0 recorded in Q2 2025.
  • Anika Therapeutics' Change in Cash's 5-year high stood at $5.6 million during Q3 2023, with a 5-year trough of -$14.7 million in Q2 2023.
  • In the last 5 years, Anika Therapeutics' Change in Cash had a median value of -$1.4 million in 2022 and averaged -$2.0 million.
  • In the last 5 years, Anika Therapeutics' Change in Cash plummeted by 147450.8% in 2023 and then surged by 116233.48% in 2025.
  • Quarter analysis of 5 years shows Anika Therapeutics' Change in Cash stood at $3.4 million in 2021, then crashed by 142.52% to -$1.4 million in 2022, then surged by 252.83% to $2.2 million in 2023, then plummeted by 335.06% to -$5.2 million in 2024, then surged by 192.59% to $4.8 million in 2025.
  • Its Change in Cash was $4.8 million in Q3 2025, compared to -$204000.0 in Q2 2025 and -$3.8 million in Q1 2025.